Warning! GuruFocus detected
3 Severe warning signs
with XLO.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Xilio Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US98422T1007
Description
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.79 | |||||
| Equity-to-Asset | 0.25 | |||||
| Debt-to-Equity | 0.46 | |||||
| Debt-to-EBITDA | -0.14 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -9.16 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 56.4 | |||||
| 3-Year EPS without NRI Growth Rate | 57 | |||||
| 3-Year FCF Growth Rate | 71.3 | |||||
| 3-Year Book Growth Rate | -61.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 77.01 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.67 | |||||
| 9-Day RSI | 40.46 | |||||
| 14-Day RSI | 43.48 | |||||
| 3-1 Month Momentum % | -27.34 | |||||
| 6-1 Month Momentum % | 19.38 | |||||
| 12-1 Month Momentum % | 32.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.21 | |||||
| Quick Ratio | 2.21 | |||||
| Cash Ratio | 2.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.7 | |||||
| Shareholder Yield % | 0.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -940.18 | |||||
| Net Margin % | -918.05 | |||||
| FCF Margin % | -289.69 | |||||
| ROE % | -216.38 | |||||
| ROA % | -76.81 | |||||
| ROIC % | -168.61 | |||||
| 3-Year ROIIC % | 188.16 | |||||
| ROC (Joel Greenblatt) % | -593.55 | |||||
| ROCE % | -130.99 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.52 | |||||
| PB Ratio | 2.03 | |||||
| Price-to-Tangible-Book | 2.02 | |||||
| EV-to-EBIT | 0.11 | |||||
| EV-to-EBITDA | 0.11 | |||||
| EV-to-Revenue | -1.03 | |||||
| EV-to-FCF | 0.36 | |||||
| Price-to-Net-Current-Asset-Value | 5.25 | |||||
| Price-to-Net-Cash | 19.7 | |||||
| Earnings Yield (Greenblatt) % | 909.09 | |||||
| FCF Yield % | -44.94 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:XLO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xilio Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6.344 | ||
| EPS (TTM) ($) | -1.28 | ||
| Beta | -0.58 | ||
| 3-Year Sharpe Ratio | -0.52 | ||
| 3-Year Sortino Ratio | -0.7 | ||
| Volatility % | 95.63 | ||
| 14-Day RSI | 43.48 | ||
| 14-Day ATR ($) | 0.09752 | ||
| 20-Day SMA ($) | 0.856435 | ||
| 12-1 Month Momentum % | 32.38 | ||
| 52-Week Range ($) | 0.58 - 1.93 | ||
| Shares Outstanding (Mil) | 51.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xilio Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xilio Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Xilio Therapeutics Inc Frequently Asked Questions
What is Xilio Therapeutics Inc(XLO)'s stock price today?
The current price of XLO is $0.79. The 52 week high of XLO is $1.93 and 52 week low is $0.58.
When is next earnings date of Xilio Therapeutics Inc(XLO)?
The next earnings date of Xilio Therapeutics Inc(XLO) is 2025-04-01 Est..
Does Xilio Therapeutics Inc(XLO) pay dividends? If so, how much?
Xilio Therapeutics Inc(XLO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers